利福平-硝唑尼特联合用药，而非利福平-异烟肼-吡嗪酰胺-乙胺丁醇，可在中性 pH 缺氧条件下杀死休眠状态的结核分枝杆菌。
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
机构信息
Dipartimento di Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy.
Organismo Notificato Unificato, Istituto Superiore di Sanità, Rome, Italy.
出版信息
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00273-19. Print 2019 Jul.
Abstract
The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.
摘要
利福平、硝唑尼特、PA-824 和苏替唑利的活性在模拟干酪样肉芽肿（低氧 pH7.3）的条件下进行了测试，并与用于人类治疗的利福平-异烟肼-吡嗪酰胺-乙胺丁醇（R-I-Z-E）组合进行了比较。通过 CFU 和 MGIT960 中的再生长监测分枝杆菌的活力。如 MGIT 中无再生长所示，含有利福平-硝唑尼特的组合，而不是 R-I-Z-E，可在 28 至 35 天内杀死休眠细胞。这些观察结果在设计新的结核病治疗方法方面可能很重要。
相似文献
1
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00273-19. Print 2019 Jul.
2
Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02296-16. Print 2017 Mar.
3
Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis.
Am Rev Respir Dis. 1977 Oct;116(4):627-35. doi: 10.1164/arrd.1977.116.4.627.
4
Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.
Antimicrob Agents Chemother. 2013 Mar;57(3):1428-33. doi: 10.1128/AAC.02154-12. Epub 2013 Jan 7.
5
Bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide on Mycobacterium tuberculosis in vitro.
Indian J Med Res. 1993 Jul;97:145-50.
6
Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
Diagn Microbiol Infect Dis. 2004 Oct;50(2):103-7. doi: 10.1016/j.diagmicrobio.2004.04.001.
7
Delamanid Kills Dormant Mycobacteria and in a Guinea Pig Model of Tuberculosis.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02402-16. Print 2017 Jun.
8
Fighting tuberculosis by drugs targeting nonreplicating bacilli.
Int J Mycobacteriol. 2017 Jul-Sep;6(3):213-221. doi: 10.4103/ijmy.ijmy_85_17.
9
In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against mycobacterium tuberculosis.
Tubercle. 1988 Sep;69(3):193-5. doi: 10.1016/0041-3879(88)90021-9.
10
Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.00840-18. Print 2018 Nov.
引用本文的文献
1
Identification of Rv1133c (MetE) as a marker of replication and as a highly immunogenic antigen with potential immunodiagnostic power.
Front Immunol. 2024 Oct 4;15:1464923. doi: 10.3389/fimmu.2024.1464923. eCollection 2024.
2
The pipeline for drugs for control and elimination of neglected tropical diseases: 2. Oral anti-infective drugs and drug combinations for off-label use.
Parasit Vectors. 2023 Oct 31;16(1):394. doi: 10.1186/s13071-023-05909-8.
3
Eradication of Drug-Tolerant 2022: Where We Stand.
Microorganisms. 2023 Jun 6;11(6):1511. doi: 10.3390/microorganisms11061511.
4
Challenges & Solutions for Recent Advancements in Multi-Drugs Resistance Tuberculosis: A Review.
Microbiol Insights. 2023 Jan 30;16:11786361231152438. doi: 10.1177/11786361231152438. eCollection 2023.
5
Responding to the post-pandemic crisis: post-exposure prophylaxis for TB.
Int J Tuberc Lung Dis. 2022 Sep 1;26(9):807-810. doi: 10.5588/ijtld.22.0342.
6
Activity of Drug Combinations against Grown in Aerobic and Hypoxic Conditions.
Microorganisms. 2022 Jul 14;10(7):1421. doi: 10.3390/microorganisms10071421.
7
The Dark Side of the COVID-19 Treatments on Infection.
Mediterr J Hematol Infect Dis. 2022 Mar 1;14(1):e2022021. doi: 10.4084/MJHID.2022.021. eCollection 2022.
8
Types and functions of heterogeneity in mycobacteria.
Nat Rev Microbiol. 2022 Sep;20(9):529-541. doi: 10.1038/s41579-022-00721-0. Epub 2022 Apr 1.
9
Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.
Microorganisms. 2021 Nov 11;9(11):2335. doi: 10.3390/microorganisms9112335.
10
Targeting Autophagy as a Strategy for Developing New Vaccines and Host-Directed Therapeutics Against Mycobacteria.
Front Microbiol. 2021 Jan 14;11:614313. doi: 10.3389/fmicb.2020.614313. eCollection 2020.
本文引用的文献
1
Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.
mBio. 2018 Nov 20;9(6):e02192-18. doi: 10.1128/mBio.02192-18.
2
Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.02266-17. Print 2018 Feb.
3
Fighting tuberculosis by drugs targeting nonreplicating bacilli.
Int J Mycobacteriol. 2017 Jul-Sep;6(3):213-221. doi: 10.4103/ijmy.ijmy_85_17.
4
Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
Ann Intern Med. 2017 Aug 15;167(4):248-255. doi: 10.7326/M17-0609. Epub 2017 Aug 1.
5
Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent.
Curr Drug Discov Technol. 2018;15(3):201-213. doi: 10.2174/1570163814666170727130003.
6
Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00226-17. Print 2017 Jun.
7
Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02296-16. Print 2017 Mar.
8
Prediction of Drug Penetration in Tuberculosis Lesions.
ACS Infect Dis. 2016 Aug 12;2(8):552-63. doi: 10.1021/acsinfecdis.6b00051. Epub 2016 Jul 6.
9
Mycobacterium tuberculosis gene expression at different stages of hypoxia-induced dormancy and upon resuscitation.
J Microbiol. 2016 Aug;54(8):565-72. doi: 10.1007/s12275-016-6150-4. Epub 2016 Aug 2.
10
Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis.
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1532-1540. doi: 10.1164/rccm.201604-0769OC.
Zotero 插件